News

Financial experts point out that what you don’t know you don’t know can hinder you.

The FDA has set a PDUFA goal date of August 29, 2023. Bevacizumab-vikg, if approved, is expected to receive 12 years of regulatory exclusivity in the United States.

Preliminary data from the three-year, international study demonstrate safety and efficacy of NVK002 as a potential treatment for the progression of myopia in children.

Genentech announced this week that faricimab-svoa (Vabysmo) achieved its primary endpoint of non-inferiority compared to aflibercept in RVO in the BALATON and COMINO clinical trials.

A previously uncharacterized area of the protein known as RPE65 spontaneously turns spiral-shaped when it encounters intracellular membranes, or thin structures that surround different parts of a cell.

According to investigators, surgeons should be aware of the high prevalence of zonular weakness and cystoid macular edema, which may warrant additional preparation in these patients.

CEO Rob Thornhill discusses the features of the device, as well as plans for a new technology called ZEPTOLINK which combines the company’s novel ZEPTO technology with any phaco device.

The 10-year retrospective ALOFT study details the importance of digital remote monitoring for patients diagnosed with age-related macular degeneration.

Teprotumumab-trbw is the first and only medicine approved by the FDA for the treatment of thyroid eye disease.

A team of investigators evaluated VA outcomes after cataract surgery and the factors associated with good visual outcomes in a population of patients diagnosed with type 2 diabetes.

There literally are not enough hours in a day to allow physicians to comply with all the recommendations emanating from the various constituencies involved in issuing guidelines.

Vivek Patel, MD, discusses issues that could threaten sight during presentation at the American Academy of Ophthalmology annual meeting in Chicago.

Ula V. Jurkunas, MD, discusses a presentation she gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of limbal stem cells to treat corneal blindness.

The COVID-19 pandemic has led to greater comfort with robotic telepresence in eye screenings.

According to a study, health disparities impact the rates of pediatric ophthalmology visits.

According to Jennifer Loh, MD, women achieve significantly better symptom relief than men.

The company noted that the pediatric exclusivity determination is based on data from two Phase 3 trials – BUTTERFLEYE and FIREFLEYE.

An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.

According to NEXGEL, the patch is expected be available for ophthalmologists to offer to their patients in the first half of 2023.

The company noted the phase 3 study looked at MicroLine as a potential on-demand treatment for presbyopia.

According to Mark Packer, MD, FACS, observations include key data points and clinical implications.

At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.

LENZ Therapeutics has unveiled positive topline data from its INSIGHT study achieved by 2 formulations to treat presbyopia.

Harvey Uy, MD, has been using the Ally adaptive cataract treatment system at his clinic in the Philippines, and it is allowing him to be more efficient.

Lisa M. Nijm, MD, JD, shares highlights from the Real World Ophthalmology 'After Dark' networking reception held at the American Academy of Ophthalmology annual meeting. The next Real World Ophthalmology meeting on November 5—which will be virtual—will cover important clinical, business, and personal growth areas for young ophthalmologists.

According to a BBC News report, the woman showered while wearing her lenses and she contracted a rare parasite infection called Acanthamoeba keratitis.

According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations.

Baseline age, best-corrected visual acuity, and central subfield thickness play role in predicting the efficacy of both drugs.